JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Elenco Azioni・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Chiusa

SettoreSettore sanitario

20.95 -1.5

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

20.85

Massimo

21.21

Metriche Chiave
By Trading Economics
Entrata	-14M -50M
Vendite	12M 128M
Margine di Profitto	-39.506
Dipendenti	1,784
EBITDA	-17M -48M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+63.74% upside

Dividendi
By Dow Jones
Utili prossimi	7 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	261M 2.5B
Apertura precedente	22.45
Chiusura precedente	20.95

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

28.13 / 31.12 Supporto e resistenza

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 mag 2026, 23:43 UTC

Principali Notizie su Eventi

New Zealand's Unemployment Rate Falls in 1Q

5 mag 2026, 23:20 UTC

Azioni calde

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 mag 2026, 21:48 UTC

Utili

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 mag 2026, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

5 mag 2026, 23:39 UTC

Discorsi di Mercato

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 mag 2026, 22:26 UTC

Discorsi di Mercato

AMD Data-Center Business Continues to Surge -- Market Talk

5 mag 2026, 22:20 UTC

Discorsi di Mercato

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 mag 2026, 22:08 UTC

Utili

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 mag 2026, 22:07 UTC

Utili

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mag 2026, 21:48 UTC

Utili

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 mag 2026, 21:48 UTC

Utili

Pan American Silver 1Q Rev $1.2B >PAAS

5 mag 2026, 21:42 UTC

Utili

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mag 2026, 21:38 UTC

Utili

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mag 2026, 21:30 UTC

Utili

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mag 2026, 21:29 UTC

Utili

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mag 2026, 21:26 UTC

Utili

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 mag 2026, 21:25 UTC

Utili

Alcon Inc. 1Q EPS 39c >ALC.EB

5 mag 2026, 21:25 UTC

Utili

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 mag 2026, 21:24 UTC

Utili

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mag 2026, 21:18 UTC

Utili

Mistras Backs 2026 Rev $730M-$750M >MG

5 mag 2026, 21:17 UTC

Utili

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 mag 2026, 21:15 UTC

Utili

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 mag 2026, 21:12 UTC

Utili

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 mag 2026, 21:11 UTC

Utili

SSR Mining 1Q Rev $581.8M >SSRM

5 mag 2026, 21:10 UTC

Utili

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 mag 2026, 21:10 UTC

Utili

SSR Mining 1Q EPS $1.16 >SSRM

5 mag 2026, 21:08 UTC

Utili

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mag 2026, 21:01 UTC

Utili

Intact Financial 1Q EPS C$4.12 >IFC.T

5 mag 2026, 21:01 UTC

Azioni calde

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

5 mag 2026, 20:59 UTC

Utili

Palantir Beat on Every Key Earnings Metric. Why Its Stock Still Fell. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

63.74% in crescita

Previsioni per 12 mesi

Media 35.27 USD 63.74%

Alto 47 USD

Basso 21.8 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 4 che hanno fornito valutazioni azionarie a Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

28.13 / 31.12Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bullish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.